×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📊
Dashboards
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Participants
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Dashboards
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Participants
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
←
Home
/
Wiki
/
Experiment: Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
experiment
596 words
Contents
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FTD
No AI portrait yet
Generate portrait ✦
Agent Input
Related Hypotheses (30)
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.98
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.82
SASP-Driven Aquaporin-4 Dysregulation
Score: 0.78
Selective HDAC3 Inhibition with Cognitive Enhancement
Score: 0.78
Circadian Clock-Autophagy Synchronization
Score: 0.76
Senescence-Activated NAD+ Depletion Rescue
Score: 0.76
Circadian-Synchronized Proteostasis Enhancement
Score: 0.74
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.74
Senescence-Induced Lipid Peroxidation Spreading
Score: 0.73
Circadian Rhythm Entrainment of Reactive Astrocytes
Score: 0.72
Circadian-Synchronized LRP1 Pathway Activation
Score: 0.71
TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.71
Lysosomal Enzyme Trafficking Correction
Score: 0.71
Complement C1q Mimetic Decoy Therapy
Score: 0.69
Extracellular Matrix Stiffness Modulation
Score: 0.69
CX43 hemichannel engineering enables size-selective mitochon
Score: 0.69
Chaperone-Mediated APOE4 Refolding Enhancement
Score: 0.68
Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu
Score: 0.67
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.67
Biorhythmic Interference via Controlled Sleep Oscillations
Score: 0.66
pg 1/2
Next →
Related Analyses (30)
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · completed
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
Extracellular vesicle biomarkers for early AD detection
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Mitochondrial transfer between neurons and glia
neurodegeneration · completed
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · completed
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Show 25 more
Related Experiments (30)
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Frontal and Temporal Lobe Selective Vulnerability in FTD — M
validation · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
FTD Microglia Role: Protective vs Destructive Mechanism Stud
validation · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
Show 25 more
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...